CNBP and cardiovascular disorder: This PUFA can inhibit the production of sterol regulatory element-binding protein (SREBP)-1c, which leads to reduced de novo lipogenesis and accumulation of TG in the liver, resulting in lower organ weight and less liberation of very-low-density lipoprotein (VLDL) and TG in the blood, vital factors for reducing risks related to cardiovascular diseases and metabolic inflammation [18,19,31].